Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
The present invention is directed to compositions, methods and kits for regulation of gene therapies for Huntington's Disease, including, without limitation, reversible gene therapies and allele-specific therapies.
1. A deoxyribonucleic acid (DNA) sequence comprising:
(1) a first sequence, said first sequence having a 5′ end and a 3′ end; and
(2) a second sequence, said second sequence having a 5′ end and a 3′ end; and
(3) a first pair of flanking sequences, wherein a first member of the first pair is located upstream of the 5′ end of the first sequence and a second member of the first pair is located downstream of the 3′ end of the second sequence; and
(4) a second pair of flanking sequences, wherein a first member of the second pair is located downstream of the 3′ end of a first member of the first pair and upstream of the 5′ end of the first sequence; and a second member of the second pair is located downstream of the 3′ end of the first sequence and upstream of the 5′ end of the second sequence; wherein:
one of the first sequence or the second sequence encodes a siRNA or shRNA capable of reducing mutated huntingtin and the other of the first sequence or the second sequence encodes a brain-derived neurotrophic factor (BDNF),
the first sequence is excisable from said deoxyribonucleic acid sequence upon exposure of said deoxyribonucleic acid sequence to a second sequence modifier that recognizes the second pair of flanking sequences, and either:
a) the second sequence is excisable from said deoxyribonucleic acid sequence upon exposure of said deoxyribonucleic acid sequence to a first sequence modifier that recognizes the first pair of flanking sequences, or
b) both the first and second sequences are excisable together from the said deoxyribonucleic acid sequence upon exposure of said deoxyribonucleic acid sequence to the first sequence modifier; and
wherein the first member of the first pair of flanking sequences is located upstream of the 5′ end of the first member of the second pair.
2. The DNA sequence of claim 1 , wherein said siRNA or shRNA is capable of reducing mutated huntingtin in an allele-specific manner and comprises a first strand and a second strand, each of said strands being 19-29 nucleotides long, and wherein the first strand comprises a sequence encoding SEQ ID NO: 65.
3. The DNA sequence of claim 1 , wherein:
the first sequence modifier is different from the second sequence modifier;
the first sequence modifier is selected from the group consisting of Cre recombinase, FLP recombinase, and phiC31 recombinase; and
the second sequence modifier is selected from the group consisting of Cre recombinase, FLP recombinase, and phiC31 recombinase.
4. The DNA sequence of claim 1 , included within a viral vector.
5. The DNA sequence of claim 4 , wherein the viral vector is an AAV vector.
6. The DNA sequence of claim 1 , wherein the first or second sequence is operably linked to a regulatory sequence.
7. The DNA sequence of claim 6 , wherein the regulatory sequence is a promoter.
8. The DNA sequence of claim 7 , wherein the promoter is a constitutively active promoter.
9. The DNA sequence of claim 7 , wherein the promoter is a tissue- or organ-specific promoter.
10. The DNA sequence of claim 7 , wherein the promoter is one selected from the group consisting of a cytomegalovirus (CMV) promoter, a SV40 early promoter region, a Rous sarcoma virus (RSV) promoter, a herpes thymidine kinase (TK) promoter, a chicken beta-actin promoter, a RNA polymerase III promoter, a MMLV-LTR promoter, and an EF1α promoter.
11. The DNA sequence of claim 10 , wherein the RNA polymerase III promoter is one selected from the group consisting of U6, H1, 7SK and 7SL promoters.